SA Asks: Which oncology companies are attractive M&A targets?

Stock Information for Adaptimmune Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adaptimmune Therapeutics plc

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.